| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
94,670,000 |
| Market
Cap: |
90.88(M) |
| Last
Volume: |
940,193 |
Avg
Vol: |
714,677 |
| 52
Week Range: |
$0.754 - $7.66 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Assertio Therapeutics is a pharmaceutical company. Co.'s primary marketed products include: INDOCIN® (indomethacin) Suppositories and INDOCIN® (indomethacin) Oral Suspension, which is a suppository form and oral solution of indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), approved for moderate to severe rheumatoid arthritis, ankylosing spondylitis and osteoarthritis; CAMBIA® (diclofenac potassium for oral solution), which is a prescription NSAID indicated for the acute treatment of migraine attacks in adults; and Otrexup® (methotrexate) injection, used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Peisert Daniel A. |
SVP and CFO |
• – – |
2019-02-06 |
4 |
D |
$4.48 |
$10,389 |
D/D |
(2,319) |
15,356 |
|
- |
|
| Peisert Daniel A. |
SVP and CFO |
• – – |
2019-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,700 |
17,675 |
|
- |
|
| Higgins Arthur J |
Director, President and CEO |
• • – |
2019-02-06 |
4 |
D |
$4.48 |
$84,793 |
D/D |
(18,927) |
87,879 |
|
- |
|
| Higgins Arthur J |
Director, President and CEO |
• • – |
2019-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
62,400 |
106,806 |
|
- |
|
| Mckee William |
Director |
– • – |
2018-12-14 |
4 |
AS |
$4.07 |
$40,693 |
D/D |
(10,000) |
9,512 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2018-12-03 |
4 |
S |
$4.84 |
$40,725 |
D/D |
(8,421) |
42,089 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2018-12-03 |
4 |
OE |
$1.49 |
$22,350 |
D/D |
15,000 |
50,510 |
|
- |
|
| Higgins Arthur J |
Director, President and CEO |
• • – |
2018-12-01 |
4 |
D |
$4.99 |
$50,973 |
D/D |
(10,215) |
44,406 |
|
- |
|
| Higgins Arthur J |
Director, President and CEO |
• • – |
2018-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,861 |
54,621 |
|
- |
|
| Gosling Matthew M |
SVP, General Counsel |
• – – |
2018-05-11 |
4 |
S |
$7.07 |
$139,095 |
D/D |
(19,674) |
0 |
|
- |
|
| Gosling Matthew M |
SVP, General Counsel |
• – – |
2018-03-31 |
4 |
D |
$6.59 |
$68,048 |
D/D |
(10,326) |
19,674 |
|
- |
|
| Moretti August J |
Chief Financial Officer & SVP |
• – – |
2018-03-31 |
4 |
D |
$6.59 |
$45,965 |
D/D |
(6,975) |
74,447 |
|
- |
|
| Gosling Matthew M |
SVP, General Counsel |
• – – |
2018-03-07 |
4 |
S |
$6.58 |
$299,515 |
D/D |
(45,519) |
0 |
|
- |
|
| Higgins Arthur J |
President and CEO |
• • – |
2017-12-14 |
4 |
B |
$8.16 |
$612,000 |
D/D |
75,000 |
111,760 |
2.81 |
- |
|
| Moretti August J |
Chief Financial Officer & SVP |
• – – |
2017-12-01 |
4 |
D |
$7.11 |
$73,489 |
D/D |
(10,336) |
58,949 |
|
- |
|
| Gosling Matthew M |
SVP, General Counsel |
• – – |
2017-12-01 |
4 |
D |
$7.11 |
$98,210 |
D/D |
(13,813) |
43,602 |
|
- |
|
| Higgins Arthur J |
President and CEO |
• • – |
2017-12-01 |
4 |
A |
$7.11 |
$93,148 |
D/D |
13,101 |
36,760 |
|
- |
|
| Staple Peter D |
Director |
– • – |
2017-12-01 |
4 |
OE |
$1.49 |
$22,350 |
I/I |
15,000 |
117,534 |
|
- |
|
| Vargas Thadd M |
SVP, Business Development |
• – – |
2017-06-13 |
4 |
S |
$9.53 |
$1,930,732 |
D/D |
(202,387) |
0 |
|
- |
|
| Vargas Thadd M |
SVP, Business Development |
• – – |
2017-06-13 |
4 |
OE |
$6.08 |
$1,036,083 |
D/D |
160,820 |
160,820 |
|
- |
|
| Higgins Arthur J |
President and CEO |
• • – |
2017-06-12 |
4 |
B |
$9.92 |
$148,800 |
I/I |
15,000 |
15,000 |
2.66 |
- |
|
| Gosling Matthew M |
SVP, General Counsel |
• – – |
2017-05-11 |
4 |
S |
$11.37 |
$673,300 |
D/D |
(59,212) |
20,665 |
|
- |
|
| Vargas Thadd M |
Senior VP, BD |
• – – |
2017-05-11 |
4 |
S |
$12.03 |
$601,250 |
D/D |
(50,000) |
41,567 |
|
- |
|
| Srinivas Rao |
SVP and Chief Medical Officer |
• – – |
2017-04-02 |
4 |
D |
$12.55 |
$11,797 |
D/D |
(940) |
19,527 |
|
- |
|
| Gosling Matthew M |
SVP, General Counsel |
• – – |
2017-04-02 |
4 |
D |
$12.55 |
$11,797 |
D/D |
(940) |
79,877 |
|
- |
|
165 Records found
|
|
Page 3 of 7 |
|
|
0.09 (8.57%) 
